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The mammalian target of rapamycin complex 1 (mTORC1) is a molecular hub that regulates protein
synthesis in response to a number of extracellular stimuli. Cyclic AMP (cAMP) is considered to be an
important second messenger that controls mTOR; however, the signaling components of this pathway have not
yet been elucidated. Here, we identify cAMP phosphodiesterase 4D (PDE4D) as a binding partner of Rheb that
acts as a cAMP-specific negative regulator of mTORC1. Under basal conditions, PDE4D binds Rheb in a
noncatalytic manner that does not require its cAMP-hydrolyzing activity and thereby inhibits the ability of
Rheb to activate mTORC1. However, elevated cAMP levels disrupt the interaction of PDE4D with Rheb and
increase the interaction between Rheb and mTOR. This enhanced Rheb-mTOR interaction induces the
activation of mTORC1 and cap-dependent translation, a cellular function of mTORC1. Taken together, our
results suggest a novel regulatory mechanism for mTORC1 in which the cAMP-determined dynamic interac-
tion between Rheb and PDE4D provides a key, unique regulatory event. We also propose a new role for PDE4
as a molecular transducer for cAMP signaling.
Cyclic AMP (cAMP) is a second messenger that is involved in
intracellular signaling in response to a number of membrane-
impermeable hormones (61, 80). cAMP plays a fundamental role
in a multitude of cellular processes, including gene transcription,
cell adhesion, and ion channel gating (9, 81, 90). cAMP levels are
delicately regulated by the coordinated control of its rate of syn-
thesis via adenylyl cyclase activity and its rate of degradation via a
large family of cAMP-hydrolyzing phosphodiesterases (PDEs) (9,
16, 31, 49). Of these PDEs, the cAMP-specific PDE4 family is
widely expressed and is the current therapeutic target of selective
inhibitors for the treatment of inflammatory diseases, such as
asthma and chronic obstructive pulmonary disease, as well as
depression and cognitive deficits (31, 34). Four gene families
encode the large family of PDE4 isoforms, which have similar
catalytic activities but distinct cellular functions. These differences
are due to differences in specific intracellular targeting and sig-
naling complex formation with various binding partners, which
generate the temporal and spatial dynamics of cAMP levels (19,
31, 32, 57, 89).
Members of the phosphodiesterase 4D (PDE4D) subfamily are
widely expressed (17, 32, 33), and the functional roles of specific
PDE4 isoforms are intimately connected with their ability to in-
teract with specific binding partners, such as the scaffold proteins
RACK1 (7, 94), myomegalin (87), -arrestin (5, 50), AKAPs (20,
55, 56, 75, 82), DISC1 (58), Spectrin (18), and Ndel (15). It is now
generally accepted that distinct PDE4 isoforms establish the com-
partmentalization of cAMP signaling in cells by shaping cAMP
gradients around themselves and bound proteins, thereby con-
trolling the function of cAMP effectors in these complexes (19, 31,
57, 63, 89). However, it is also accepted that PDE4 isoforms can
undergo conformational changes in response to posttranslational
modifications (1, 6, 28, 46), sequestration to scaffolds (94), and
binding to inhibitors and substrates (32, 74, 85). Here, we uncover
a novel functional role of a PDE4 isoform as a cAMP effector
rather than through simply terminating cAMP signaling via
cAMP hydrolysis.
mTOR interacts with Raptor to form mTOR complex 1
(mTORC1), which plays an essential role in protein synthesis
in mammals in response to various signals, including insulin,
nutrients, amino acids, and cellular energy status (37, 39, 67,
91). The best-characterized downstream effectors of mTORC1
are the two translational regulators S6 kinase 1 (S6K1) and 4E
binding protein 1 (4EBP1) (11, 12, 25). In response to up-
stream signals, mTORC1 directly phosphorylates S6K1 and
4EBP1, which induces translation initiation (24, 30, 53). Al-
though mTOR recognizes various environmental cues and
each signal can regulate mTOR activity, the precise molecular
mechanisms of how diverse signals control mTOR remain un-
clear. Indeed, even cAMP has been identified as an activator of
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mTORC1, although the details of the mechanism of mTORC1
regulation by cAMP are not well understood (43, 78).
Several upstream regulators of mTOR have been identified
(23, 38, 65, 66, 86). Rheb, a member of the Ras-related small
GTPases, is one of the best-characterized upstream activators
of mTORC1 (2, 68, 76, 93). Like the other small GTPases, the
activity of Rheb is regulated by guanine nucleotide binding
status. Conversely, the best-characterized negative regulator of
mTOR is the tuberous sclerosis complex (TSC1/TSC2), which
has GTPase-activating protein (GAP) activity toward Rheb. A
number of environmental signals, such as insulin, nutrients,
and cellular energy status, are recognized by the TSC complex,
which controls the guanine nucleotide binding status of Rheb
and thereby regulates mTOR activity (10, 23, 38, 51, 84, 96). In
addition, phosphatidic acid, phospholipase D, PRAS40, and
Rag GTPase have been identified as mTOR regulators that
respond to specific signals (21, 26, 65, 66, 79, 86). However,
there is still no clear relationship between cAMP signaling
components and mTOR regulators.
In this study, we identified cAMP-specific PDE4D as a novel
Rheb binding partner that serves as a sensor for cAMP signal-
ing. This allows cAMP, through PDE4D, to release Rheb for
the activation of mTORC1. This novel mechanism suggests
that cAMP signals are transduced to mTORC1, and then to
cap-dependent translation, through a novel pathway involving
the dynamic interaction between PDE4D and Rheb.
MATERIALS AND METHODS
Antibodies and materials. Anti-Rheb (C19) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), and anti-mTOR-phospho-PS6K1
(pS6K1) (Thr389), -S6K1, -p4EBP1 (Thr37/46), -4EBP1, -pERK (Thr202/
Tyr204), -extracellular signal-regulated kinase (anti-ERK), -pAKT (Ser473), and
-AKT antibodies and rapamycin were obtained from Cell Signaling (Beverly,
MA). 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS),
H89, forskolin, cAMP, cyclic GMP (cGMP), GTPS, GDPS, isoproterenol, and
anti-FLAG monoclonal antibodies were purchased from Sigma (St. Louis, MO).
Compound C and PD98059 were purchased from Merck (Darmstadt, Germany).
Anti-PDE4D polyclonal antibodies were made as previously reported (8). Anti-
hemagglutinin (HA) 12CA5 antibodies were harvested from the supernatants of
hybridoma cell lines (44). Protein A-Sepharose and protein G-Sepharose beads were
purchased from RepliGen (Needham, MA) and Pierce (Rockford, IL), respectively.
7-Methyl-GTP Sepharose 4B was purchased from GE (Buckinghamshire, United
Kingdom). Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial
Institute (RPMI) 1640 medium, and Lipofectamine were obtained from Invitrogen
(Carlsbad, CA). Recombinant 4EBP1 was purchased from Stratagene (Garden
Grove, CA). Horseradish peroxidase-conjugated goat anti-mouse IgA, IgM, and IgG
and peroxidase-conjugated goat anti-rabbit IgG were purchased from Kierkegaard
and Perry Laboratories (Gaithersburg, MD). Peroxidase-conjugated donkey anti-
goat IgG antibodies were obtained from Santa Cruz Biotechnology. An enhanced
chemiluminescence kit was purchased from Amersham Biosciences International
(Buckinghamshire, United Kingdom).
Plasmids and RNA interference. The HA-tagged Rheb clone was kindly pro-
vided by Ariel F. Castro (Indiana University School of Medicine). Myc-mTOR
and HA-Raptor were kindly provided by David M. Sabatini (Massachusetts
Institute of Technology). Myc-S6K, FLAG-TSC1, and FLAG-TSC2 were kindly
provided by John Blenis (Harvard Medical School). The mammalian expression
vectors for PDE4D1, PDE4D2, and PDE4D5 were constructed as previously
reported (8). Green fluorescent protein (GFP)-Rheb, His-Rheb, and glutathione
S-transferase (GST)-Rheb were constructed as previously reported (44). The
full-length coding region of Raptor obtained by PCR was subcloned into the
N-terminal pFlag-CMV2 vector with EcoRI and BamHI. The full-length coding
regions of PDE4D1 and PDE4D2 obtained by PCR were subcloned into the
N-terminal pFlag-CMV2 vector with EcoRI and BamHI. The full-length coding
region of PDE4D5 obtained by PCR was subcloned into the N-terminal pFlag-
CMV2 vector with HindIII and EcoRI. The catalytic region of PDE4D5 obtained
by PCR was subcloned into the N-terminal pFlag-CMV2 vector with EcoRI and
BamHI. To introduce the D556A mutation into PDE4D5, FLAG-PDE4D5 was
PCR amplified by using the following oligomers: sense oligomer 5-AAA CTC
TGA ACT AGC GCT GAT GTA CAA TG-3 and antisense oligomer 5-CAT
TGT ACA TCA GCG CTA GTT CAG AGT TT-3. DNA fragments were
ligated into the pFlag-CMV2 vector previously digested with HindIII and EcoRI.
To construct the GST fusion PDE4D5 fragments, each fragment of PDE4D5
obtained by PCR was subcloned into the pGEX-4T-1 vector cut with EcoRI and
BamHI. The small interfering RNAs (siRNAs) for PDE4D were located in the
region of the PDE4D5 transcript that codes for residues 456 to 461 (5-AAGA
ACUUGCCUUGAUGUACA-3) and were purchased from Dharmacon (50).
The small hairpin RNA (shRNA) for Rheb was constructed in the pLKO shRNA
vector. The target sequence for Rheb1 was 5-GAGGACACTGGGAATATAT
TC-3. The bicistronic reporter pRMF with the c-myc internal ribosome entry
site (IRES) was made as previously reported (41).
Cell culture and transfection. HEK293 cells and TSC1/ and TSC1/ mouse
embryo fibroblasts (MEFs) were maintained in DMEM containing 10% fetal bovine
serum (FBS) (Cambrex, Walkersville, MD). HeLa and Ovcar3 cells were maintained
in DMEM containing 10% FBS (Gibco, Carlsbad, CA). SK-OV3 and T47D cells
were maintained in RPMI medium containing 10% FBS (Cambrex, Walkersville,
MD). Transfection was performed by using Lipofectamine according to the manu-
facturer’s instructions. Cells were allowed to express the recombinant proteins or to
knock down the target proteins by siRNA for 24 h after transfection and were then
deprived of serum for an additional 24 h. The cells were subjected to Western blot
or coimmunoprecipitation analysis.
Sample preparation and Western blot analysis. After harvesting of the
HEK293 cells, total extracts were prepared by sonication in ice-cold lysis
buffer (40 mM HEPES [pH 7.5], 120 mM NaCl, 1 mM EDTA, 10 mM
pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4,
0.5% CHAPS, 1 mM phenylmethylsulfonyl fluoride [PMSF], 5 mM MgCl2,
and protease inhibitor cocktail). The prepared cell extracts were spun at
14,000 rpm for 15 min, and the supernatant was subjected to Western blot or
coimmunoprecipitation analysis.
Quantification of cAMP. A cAMP-measuring kit was purchased from Neu-
ronex (Pohang, South Korea). The cAMP concentration in HEK293 cells was
measured by using a [3H]cAMP competition assay for evaluating interactions
with cAMP binding proteins according to the manufacturer’s instructions.
Coimmunoprecipitation. The cell extract (1 mg) was incubated with 2 g of
the indicated antibodies and protein A-Sepharose beads or protein G-Sepharose
beads. After 5 h of incubation at 4°C, the resulting pellets were washed four times
with ice-cold lysis buffer, subjected to SDS-PAGE, and immunoblotted with the
respective antibodies.
In vitro binding assay. The mapping of the Rheb binding site on PDE4D5 was
performed by incubating equal amounts of GST-PDE4D fragments with 200 ng
of purified His-tagged Rheb. After 4 h of incubation at 4°C, the resulting pellets
were washed four times with ice-cold lysis buffer, subjected to SDS-PAGE, and
immunoblotted with anti-Rheb antibodies.
Rheb nucleotide binding assay. To analyze the GTP and GDP loading status of
Rheb, recombinant HA-Rheb was transfected into HEK293 cells, and cells were
incubated in 0.5 mCi 32Pi for 4 h. These cells were harvested in buffer A (50 mM
HEPES [pH 7.4], 500 mM NaCl, 10 mM MgCl2, 1 mg/ml bovine serum albumin
[BSA], 1 mM dithiothreitol [DTT], 1% Triton X-100, and protease inhibitors).
HA-tagged Rheb was immunoprecipitated with an anti-HA antibody. Immunopre-
cipitates were washed twice each with both buffer A and buffer B (50 mM HEPES
[pH 7.4], 100 mM NaCl, 10 mM MgCl2, 0.1% Triton X-100, and protease inhibitors).
GTP and GDP bound to Rheb were released with 20 l Rheb elution buffer (5 mM
EDTA, 0.2% SDS, 5 mM DTT, 0.5 mM GDP, and 0.5 mM GTP) at 68°C for 20 min
and then resolved by thin-layer chromatography on polyethyleneimine (PEI) cellu-
lose plates with 0.75 M KH2PO4 (pH 3.4). The amount of radioactive GTP and GDP
was quantified with Multi Gauge software (Fuji).
In vitro kinase assay for mTORC1 activity. Recombinant Myc-mTOR and
FLAG-Raptor were transfected into HEK293 cells and then immunoprecipitated by
using an anti-FLAG antibody, as previously described (40). Purified 4EBP1 was used
as a substrate for the in vitro kinase assays, and the activities were measured with an
anti-phospho-4EBP1 antibody (Thr37/46). The kinase assay was performed with
kinase buffer containing 25 mM HEPES (pH 7.4), 50 mM KCl, 10 mM MgCl2, 4 mM
MnCl2, 20% glycerol, 2 mM DTT, 0.1 mM ATP, and 0.25 g 4EBP1 from the
immunoprecipitate, which was incubated for 10 min at 37°C.
m7-GTP binding assay. Cell extracts were incubated with 10 l of m7-GTP
Sepharose beads at 4°C for 4 h, and the beads were then washed four times with
ice-cold lysis buffer. The resulting pellets were subjected to SDS-PAGE and
immunoblotted with anti-4EBP1 and anti-eIF-4E antibodies (69).
Translation assay with HEK293 cells. Translation was assayed by luciferase
reporter activity. With the pRMF reporter, luciferase activities were mea-
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FIG. 1. cAMP activates mTORC1 signaling via Rheb. (A) cAMP activates mTORC1 signaling in a rapamycin-dependent manner. HEK293
cells were incubated with 10% fetal bovine serum for 36 h. After 24 h of serum deprivation, the cells were preincubated with or without serum-free
medium containing 10 nM rapamycin for 45 min and were then treated with 10 M forskolin for 5 min. The cells were lysed with buffer containing
0.5% CHAPS. Equal amounts of total cell lysates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The results
shown are representative of two independent experiments. (B) Forskolin activates mTORC1 in a dose-dependent manner. After 24 h of serum
deprivation, HEK293 cells were treated with the indicated concentrations of forskolin for 5 min. The lysates were subjected to SDS-PAGE and
immunoblotted with the respective antibodies. (C) cAMP-mediated mTORC1 activation is dependent on Rheb. HEK293 cells were transfected
with either the control or Rheb shRNA by using Lipofectamine. After 24 h, cells were depleted of serum for 24 h and then treated with 10 M
forskolin for 5 min. The lysates were immunoprecipitated (IP) with anti-Rheb antibodies. The immunoprecipitates and lysates were subjected to
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sured by using a dual-luciferase reporter assay system (Labsystems, Ramsey,
MN). Equal amounts of extract were used to assay the cap-dependent trans-
lation of Renilla luciferase (R-Luc) or IRES-dependent translation of firefly
luciferase (F-Luc). Cap-dependent translation was calculated by normalizing
the R-Luc activity to the F-Luc activity as described previously (13, 47).
RESULTS
cAMP activates mTORC1 through Rheb. To examine the
relationship between cAMP and mTORC1 and determine
whether cAMP increases mTORC1 activity, we investigated
cAMP-dependent mTORC1 activation and the requirement of
Rheb in cAMP-mediated mTORC1 signaling. As shown in Fig.
1A, we confirmed (42, 78), using forskolin, which is a direct
activator of adenylyl cyclase, that cAMP augmented the phos-
phorylation of S6K1 (T389) and 4EBP1 (T37/46), the best-
characterized downstream effectors of mTORC1 (Fig. 1A).
However, in these cells, cAMP did not alter the phosphoryla-
tion of Akt (S473), a downstream effector of mTORC2 (Fig.
1A). Furthermore, cAMP-mediated mTORC1 activation was
reduced by treatment with rapamycin, an mTORC1 inhibitor.
However, rapamycin had no effect on either Akt or Erk (T202/
Y204) phosphorylation. Despite this result, we found that
mTORC1 activity was enhanced by increasing concentrations
of the adenylyl cyclase activator forskolin (Fig. 1B). Indeed,
mTORC1 activity was increased by cAMP-elevating agonists,
such as isoproterenol and epinephrine (data not shown).
Next, we evaluated whether cAMP-mediated mTORC1 ac-
tivation requires Rheb activity. Indeed, we found that the ac-
tivation of mTORC1 by cAMP decreased when Rheb was
silenced (Fig. 1C). Furthermore, the overexpression of Rheb-
D60I, a GDP-bound dominant negative form, diminished the
levels of phospho-S6K1 and phospho-4EBP1 (Fig. 1D).
We investigated whether TSC, the GAP for Rheb, has an
effect on cAMP-mediated mTORC1 activation. As shown in
Fig. 1E, treatment with forskolin elevated the levels of phos-
pho-S6K1 in TSC1/ MEFs (Fig. 1E). However, both the
expression and phosphorylation levels of S6K1 were highly
elevated in TSC/ MEFs, while mTORC1 activity in TSC/
MEFs was not affected by forskolin (Fig. 1E). Indeed, the
coexpression of TSC1 and TSC2 had little effect on cAMP-
mediated mTORC1 activation (Fig. 1F). These results suggest
that TSC does not provide a main pathway for cAMP-medi-
ated mTORC1 regulation.
It was reported previously that cAMP can regulate a number of
signaling pathways, including AMP-activated protein kinase
(AMPK) and mitogen-activated protein kinase (MAPK), which
control mTORC1 (36, 77, 95). To examine the relationship be-
tween cAMP and known pathways that control mTORC1, we
checked cAMP-dependent mTORC1 activation under conditions
where either the AMPK or the MAPK pathways were inhibited.
The overexpression of the dominant negative form of recombi-
nant AMPK1 increased basal phosphorylation levels of S6K1,
while forskolin treatment elicited an increase in phospho-S6K1
levels similar to those seen for transfections with the vector con-
trol (Fig. 1G). Furthermore, PD98059, a MAPK inhibitor, did not
affect cAMP-mediated mTORC1 regulation (Fig. 1H). These re-
sults indicate that cAMP-mediated mTORC1 activation requires
other distinct mechanisms in addition to TSC, AMPK, and
MAPK pathways.
Protein kinase A (PKA) is a major target of cAMP (62), and
certain reports have shown that cAMP-mediated mTORC1
signaling might be affected by PKA (78). Therefore, we inves-
tigated whether cAMP-mediated mTORC1 activation re-
quired PKA in our experimental system. However, we found
that H89, a PKA inhibitor, did not have a significant effect on
mTORC1 activity (Fig. 1I). These results suggest that the
cAMP signal that we observed is linked to mTOR through
Rheb but not through either TSC or PKA.
PDE4D regulates cAMP-mediated mTORC1 activity. Next,
we tested whether an elevated cellular cAMP level would
affect mTORC1 activity. PDE4D provides the majority of
cAMP phosphodiesterase activity (80%) in HEK293 cells
(50). siRNA reagents directed toward PDE4D can efficiently
knock down the expression and, hence, the activity of all
isoforms within this subfamily without affecting the expres-
sion levels of other PDE4 subfamily members in HEK cells
(50). Using forskolin, we observed a sustained increase in
the cellular cAMP levels of PDE4D-silenced cells (50; data
not shown) and an elevation in levels of cAMP-mediated
mTORC1 activity (Fig. 2A).
SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative of two independent experiments. CTL,
shRNA vector control. (D) The level of cAMP-mediated mTORC1 activation is decreased by a Rheb dominant negative mutant. HEK293 cells
were transfected with either a GFP vector or GFP-Rheb D60I by using Lipofectamine. After 24 h, cells were depleted of serum for 24 h and then
treated with 10 M forskolin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The results
shown are representative of three independent experiments. (E) cAMP-mediated mTORC1 activation is not affected in TSC1-deficient cells.
TSC1/ and TSC1/ MEFs were depleted of serum for 8 h and then treated with 10 M forskolin for 5 min. The lysates were subjected to
SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative of three independent experiments. (F)
Overexpression of TSC1 and TSC2 has little effect on forskolin-dependent mTORC1 activation. HEK293 cells were transfected with control or
recombinant TSC1/2. After 24 h, cells were deprived of serum for 24 h and then treated with 10 M forskolin for 5 min. The lysates were subjected
to SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative of three independent experiments. Vec,
vector control. (G) Overexpression of the AMPK1 dominant negative form does not affect forskolin-dependent mTORC1 activation. HEK293
cells were transfected with the control or recombinant form of dominant-negative AMPK1. After 24 h, cells were deprived of serum for 24 h and
then treated with 10 M forskolin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The
results shown are representative of two independent experiments. DN, dominant negative. (H) Inhibition of MAPK does not affect forskolin-
dependent mTORC1 activation. After 24 h of serum deprivation, HEK293 cells were preincubated with or without serum-free medium containing
PD98059 for 30 min and then treated with 10 M forskolin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the
respective antibodies. The results shown are representative of two independent experiments. (I) Inhibition of PKA does not affect forskolin-
dependent mTORC1 activation. After 24 h of serum deprivation, HEK293 cells were preincubated with or without serum-free medium containing
H89 for 45 min and then treated with 10 M forskolin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the respective
antibodies. The results shown are representative of two independent experiments.
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Since the PDE4D5 isoform is the major species present in
HEK293 cells (50), we analyzed whether the overexpression of
recombinant forms of either wild-type (wt) PDE4D5 or a cata-
lytically inactive PDE4D5 mutant (D556A-PDE4D5) would af-
fect mTORC1 activity. The overexpression of wt PDE4D5 but not
D556A-PDE4D5 rapidly reduced intracellular cAMP levels (Fig.
2B) and PKA activity (50, 60). However, although wt PDE4D5
overexpression decreased cAMP-mediated mTORC1 activity
(Fig. 2C), unexpectedly, we found that D556A-PDE4D5 also re-
duced mTORC1 activation (Fig. 2C). Note that D556A-PDE4D5
has no observable PDE activity and does not decrease intracel-
lular cyclic AMP levels in HEK293 cells (Fig. 2B) (4, 50), since
Asp556 provides a critical component of the catalytic active site
(32). These results suggest that PDE4D5 may have a negative role
in regulating mTORC1 activation that is independent of its en-
zymatic activity.
PDE4D interacts with Rheb. Considering the observation
that PDE4D5 inhibits cAMP-mediated mTORC1 activation
independently of its catalytic activity, we hypothesized that
PDE4D5 may have an inhibitory role in mTORC1 signaling
through the association with and inhibition of a component of
the mTORC1 signaling pathway rather than through reducing
cAMP levels. Since Rheb is the immediate upstream mediator
of mTOR signaling by cAMP, we evaluated the possibility that
PDE4D5 and Rheb might interact. Ectopically expressed, re-
combinant PDE4D5 and Rheb coimmunoprecipitated (Fig.
3A). Furthermore, by coimmunoprecipitation, we also demon-
strated that endogenous PDE4D5 could be found in a complex
with endogenous Rheb in HEK293 cells (Fig. 3B) and various
other cell lines (Fig. 3C). Additionally, Rheb was also able to
interact with D556A-PDE4D5 (Fig. 3D). Furthermore, the
PDE4D1 short form and the PDE4D2 supershort form also
FIG. 2. PDE4D inhibits cAMP-mediated mTORC1 signaling. (A) PDE4D knockdown enhances mTORC1 activity. HEK293 cells were
transfected with either control or PDE4D siRNA. After 24 h, cells were deprived of serum for 24 h and then treated with 10 M forskolin for 5
min. The lysates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The bar graph at the bottom shows the
quantification of S6K1 phosphorylation. The results shown are representative of three independent experiments. Luc, luciferase control. (B) The
D556A-PDE4D5 mutant has no enzymatic activity. HEK293 cells were transfected with the indicated constructs. After 24 h, cells were deprived
of serum for 24 h and then treated with 10 M forskolin for the indicated times. The cAMP concentration in HEK293 cells was measured by using
a [3H]cAMP competition assay. The results shown are representative of two independent experiments. (C) Overexpression of both wt PDE4D5
and catalytically inactive mutant (D556A) PDE4D5 inhibits mTORC1 activity. HEK293 cells were transfected with the indicated constructs and
Myc-S6K1. After 24 h, cells were deprived of serum for 24 h and then treated with 10 M forskolin for 5 min. The lysates were subjected to
SDS-PAGE and immunoblotted with the respective antibodies. The bar graph at the bottom shows the quantification of S6K1 phosphorylation.
The results shown are representative of two independent experiments.
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coimmunoprecipitated with Rheb (Fig. 3E), suggesting that
this binding is not an isoform-specific property but is associ-
ated with regions common to all isoforms, which differ only in
their N-terminal regions.
Because Rheb is a GTPase, we investigated whether the
association with and inhibition by PDE4D extended to other
members of the GTPase superfamily or was binding specific for
Rheb. Thus, we analyzed the interaction of PDE4D5 with
several related small GTPases and the interaction of Rheb with
other PDE isotypes. Although PDE4D5 immunoprecipitated
with Rheb, it did not immunoprecipitate with either Ras or
Rap2A (Fig. 3F), and Rheb did not interact with PDE5A (Fig.
3G). These results suggest that PDE4D interacts only with
specific GTPases.
cAMP inhibits the interaction between Rheb and PDE4D.
To identify the region of PDE4D responsible for interactions
with Rheb, we generated glutathione S-transferase (GST) fu-
sions of PDE4D fragments (Fig. 4A). Using purified His-Rheb
and the GST-PDE4D fragments, we found that the catalytic
domain of PDE4D (F2) is responsible for binding to Rheb
(Fig. 4B). Because the catalytic domain of PDE4D is also the
binding region for cAMP, we tested whether elevated cAMP
levels affected the association and inhibition of Rheb by
PDE4D5. As shown in Fig. 4C, the Rheb-PDE4D interaction
was decreased upon the addition of cAMP in vitro. The cata-
lytic activity of PDE4D is not involved in the dynamic interac-
tion with Rheb, since the addition of cAMP similarly caused a
dissociation of Rheb from GST-F2-D556A (Fig. 4C). This in-
FIG. 3. PDE4D5 specifically interacts with Rheb. (A) Interaction be-
tween recombinant PDE4D5 and Rheb. HEK293 cells were transfected
with wild-type FLAG-PDE4D5 and HA-Rheb. After 36 h, the cell lysates
were immunoprecipitated with either anti-HA or anti-FLAG antibodies.
Both PDE4D5-bound Rheb and Rheb-bound PDE4D5 were analyzed by
anti-HA immunoblotting and anti-FLAG immunoblotting, respectively.
The results shown are representative of two independent experiments.
(B) Confirmation of the interaction between endogenous PDE4D5 and
Rheb. HEK293 cells were immunoprecipitated with Rheb-specific or con-
trol goat IgG antibodies. Coimmunoprecipitated PDE4D5 was analyzed
by anti-PDE4D antibodies. The results shown are representative of two
independent experiments. (C) Rheb interacts with PDE4D5 in various
cell lines. Each cell lysate was immunoprecipitated with Rheb-specific or
control goat IgG antibodies. Coimmunoprecipitated PDE4D5 was ana-
lyzed by immunoblotting with anti-PDE4D antibodies. (D) Interaction
between the PDE4D5 catalytically inactive mutant and Rheb. HEK293
cells transfected with wt PDE4D5 or D556A-PDE4D5 were immunopre-
cipitated with anti-FLAG antibodies. Coimmunoprecipitated recombi-
nant PDE4D5 was analyzed by anti-FLAG antibodies. The results shown
are representative of two independent experiments. (E) Rheb interacts
with all of the PDE4D splicing variants. HEK293 cells were transfected
with the indicated constructs. After 36 h, the cell lysates were immuno-
precipitated with anti-FLAG antibody. Coimmunoprecipitated Rheb was
analyzed by anti-Rheb antibodies. The results shown are representative of
two independent experiments. (F) PDE4D5 interacts with Rheb but not
other small GTPases. HEK293 cells were transfected with the indicated
constructs. After 36 h, the cell lysates were immunoprecipitated with
anti-HA antibodies. Coimmunoprecipitated PDE4D5 was analyzed by
anti-FLAG antibodies. The results shown are representative of two inde-
pendent experiments. (G) Rheb interacts with PDE4D5 but not PDE5A.
HEK293 cells were transfected with the indicated constructs. After 36 h,
the cell lysates were immunoprecipitated with anti-HA antibodies. Coim-
munoprecipitated PDE4D5 and mPDE5A were analyzed by anti-FLAG
antibodies. The results shown are representative of two independent ex-
periments.
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FIG. 4. cAMP-mediated dissociation of PDE4D from Rheb enhances the formation of the Rheb-mTOR complex. (A) Schematic diagram of
the GST-PDE4D fragments. (B) Rheb interacts directly with the catalytic domain of PDE4D. Each of the GST-PDE4D fragments was incubated
with purified His-Rheb. After performing the GST pulldown assay, bound Rheb was analyzed by anti-Rheb antibodies, and the amounts of the
GST-PDE4D fragments are shown by Ponceau S staining. The results shown are representative of two independent experiments. (C) cAMP, a
substrate of PDE4D, specifically disrupts the interaction between Rheb and PDE4D. GST, GST-F2 wt, or D556A mutant fragments were
incubated with His-Rheb in the presence of the indicated concentrations of cAMP or cGMP. Bound Rheb was analyzed by anti-Rheb antibodies,
and the amounts of GST-F2 are shown by Ponceau S staining. The results shown are representative of two independent experiments. (D) PDE4D5
dissociates from Rheb with increased cellular cAMP levels. HEK293 cells were treated with 10 M forskolin for the indicated times. The cell lysates
were immunoprecipitated with anti-Rheb antibodies. The immunoprecipitates were subjected to SDS-PAGE and immunoblotted with the
respective antibodies. The results shown are representative of two independent experiments. (E) PKA has no effect on the dynamic
interaction between PDE4D5 and Rheb. After 24 h of serum deprivation, HEK293 cells were preincubated with or without serum-free
medium containing 30 M H89 for 45 min and then treated with 10 M forskolin for 5 min. The cell lysates were immunoprecipitated with
anti-Rheb antibodies. The immunoprecipitates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. (F) cAMP
specifically decreases the interaction between Rheb and PDE4D5. HEK293 cells were treated with 10 nM insulin, 10 M isoproterenol, or
10 M forskolin for 5 min. The cell lysates were immunoprecipitated with anti-Rheb antibodies. The immunoprecipitates were subjected to
SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative of two independent experiments.
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teraction was not affected by the addition of cGMP (Fig. 4C),
which neither is hydrolyzed by nor binds to PDE4 (32).
To confirm the dynamic interaction, we tested whether
cAMP regulates the interaction between PDE4D and Rheb in
a cellular system. The interaction of endogenous PDE4D with
Rheb was strongly reduced under conditions of elevated cAMP
cellular levels, which was achieved by treatment with the ad-
enylyl cyclase activator forskolin (Fig. 4D). The PKA inhibitor
H89 had no effect on the ability of the elevation of cAMP levels
to disrupt the interaction between PDE4D5 and Rheb, which
correlated with the mTORC1 activity (Fig. 4E). We also ob-
served a similar result when isoproterenol, a -adrenergic re-
ceptor agonist that increases cAMP levels, was used to chal-
lenge these cells (Fig. 4F). The interaction was not affected by
insulin treatment (Fig. 4F).
Next, we analyzed whether the PDE4D5-Rheb interaction
was regulated by the guanyl-nucleotide status of Rheb. How-
ever, this interaction did not depend on the GTP/GDP status
of Rheb (Fig. 5A). Furthermore, forskolin treatment and the
overexpression of PDE4D5 had no effect on the GTP/GDP
ratio of Rheb (Fig. 5B and C). These results suggest that
cAMP, rather than the guanyl-nucleotide switching of Rheb,
FIG. 5. PDE4D5 does not affect the guanine nucleotide-bound status of Rheb. (A) The interaction between Rheb and PDE4D does not depend on
its nucleotide binding status. His-Rheb was charged with 100 mM GDPS or 100 mM GTPS. GST or GST-F2 fragments were incubated with free or
nucleotide-charged His-Rheb. After performing the GST pulldown assay, bound Rheb was analyzed by an anti-Rheb antibody, and the amounts of
GST-F2 are shown by Ponceau S staining. (B) cAMP does not increase the GTP/GDP ratio of Rheb. HEK293 cells were transfected with HA-Rheb.
After 24 h, cells were deprived of serum for 20 h and incubated with 0.5 mCi 32Pi for 4 h and then treated with 10 M forskolin for 5 min. The lysates
were subjected to an in vivo radiolabeling assay. The results shown are representative of two independent experiments. (C) Overexpression of PDE4D5
does not affect the GTP/GDP ratio of Rheb. HEK293 cells were transfected with the indicated constructs. After 36 h, cells were incubated with 0.5 mCi
32Pi for 4 h and subjected to an in vivo radiolabeling assay. The results shown are representative of two independent experiments.
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may be a direct regulator of the dynamic interaction between
PDE4D and Rheb.
PDE4D negatively regulates mTORC1. Interestingly, forsko-
lin treatment enhanced the interaction between Rheb and
mTOR, which was inversely correlated with the reduction in
the Rheb-PDE4D interaction (Fig. 6A). Since the PDE4D-
Rheb interaction was regulated by cAMP and PDE4D inhib-
ited cAMP-induced mTORC1 activity, we next determined
whether the interaction of PDE4D with Rheb affected Rheb-
stimulated mTORC1 activity. We first analyzed in vitro
mTORC1 kinase activity using purified GST-Rheb and the
PDE4D catalytic domain (F2-PDE4D). The results showed
that the increase in mTORC1 kinase activity induced by GST-
Rheb was inhibited by the addition of F2-PDE4D (Fig. 6B).
This inhibition was recovered upon the addition of cAMP but
not upon the addition of cGMP (Fig. 6C). The overexpression
of wt PDE4D5, D556A-PDE4D5, or the PDE4D catalytic do-
main fragment (F2) had negative effects on Rheb-induced
mTORC1 activation, which were reversed by increasing the
cAMP level (Fig. 6D and E). However, neither PDE4D silenc-
ing nor overexpression had any effect on non-cAMP signaling
pathways, such as insulin-induced mTORC1 activation (Fig. 6F
and G). Indeed, PDE5A overexpression did not affect
mTORC1 activity (Fig. 6H). These results strongly suggest that
PDE4D is a dynamic regulator specific for cAMP-mediated
mTORC1 activation.
PDE4D negatively regulates cap-dependent translation. Be-
cause cAMP-mediated mTORC1 activation is regulated by the
Rheb-PDE4D interaction, we wondered whether downstream
cellular processes were also affected by this interaction. The
FIG. 6. PDE4D has a negative effect on mTORC1 kinase activity. (A) cAMP enhances the interaction between Rheb and mTOR. HEK293 cells were
treated with 10 M forskolin or 10 M isoproterenol for 5 min. The cell lysates were immunoprecipitated with anti-Rheb antibodies. The immunopre-
cipitates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative of two independent
experiments. (B) The PDE4D F2 fragment inhibits mTORC1 kinase activity. Myc-mTOR and FLAG-Raptor were transfected into HEK293 cells. After
immunoprecipitation with anti-FLAG antibodies, immunoprecipitates and GTPS-loaded GST-Rheb were incubated in the absence or presence of the
F2 fragment at 37°C for 10 min. Proteins were resolved by SDS-PAGE, and the phosphorylation of 4EBP1 on Thr37/46 was analyzed by Western blotting.
The bar graph at the bottom shows the quantification of 4EBP1 phosphorylation. The results shown are representative of three independent experiments.
(C) mTORC1 activity inhibited by the F2 fragment is restored by cAMP but not cGMP. Myc-mTOR and FLAG-Raptor were transfected into HEK293
cells. After immunoprecipitation with anti-FLAG antibodies, immunoprecipitates, GTPS-loaded GST-Rheb, and the F2 fragment were incubated in the
absence or presence of cAMP or cGMP at 37°C for 10 min. Proteins were resolved by SDS-PAGE, and the phosphorylation of 4EBP1 on Thr37/46 was
analyzed by Western blotting. The bar graph at the bottom shows the quantification of 4EBP1 phosphorylation. The results shown are representative of
two independent experiments. (D) The PDE4D F2 fragment inhibits mTORC1 activity. HEK293 cells were transfected with the indicated constructs.
After 36 h, the cells were lysed, subjected to SDS-PAGE, and immunoblotted with the respective antibodies. The bar graph at the bottom shows the
quantification of S6K1 phosphorylation. The results shown are representative of three independent experiments. (E) The PDE4D F2 fragment inhibits
mTORC1 activity. HEK293 cells were transfected with the indicated constructs and Myc-S6K1. After 24 h, cells were deprived of serum for 24 h and then
treated with 10 M forskolin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The bar graph at
the bottom shows the quantification of S6K1 phosphorylation. The results shown are representative of two independent experiments. (F) PDE4D
knockdown does not affect insulin-mediated mTORC1 activity. HEK293 cells were transfected with either control or PDE4D siRNA. After 24 h, cells
were deprived of serum for 24 h and then treated with 20 nM insulin for 5 min. The lysates were subjected to SDS-PAGE and immunoblotted with the
respective antibodies. (G) PDE4D5 wt overexpression does not affect insulin-mediated mTORC1 activity. HEK293 cells were transfected with either the
control or wt PDE4D5 constructs. After 24 h, cells were deprived of serum for 24 h and then treated with 20 nM insulin for 5 min. The lysates were
subjected to SDS-PAGE and immunoblotted with the respective antibodies. (H) PDE5A does not affect mTORC1 activity. HEK 293 cells were
transfected with the indicated constructs. After 36 h, the cells were lysed, subjected to SDS-PAGE, and immunoblotted with the respective antibodies.
4D5, PDE4D5; m5A, mPDE5A.
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major cellular downstream target of mTORC1 is the regula-
tion of cap-dependent translation, in which the phosphoryla-
tion of 4EBP1 by mTORC1 releases 4EBP1 from eIF-4E for
translation initiation (52). To further confirm the role of
PDE4D in mTORC1 signaling, we evaluated cap-dependent
translation by measuring the effect of cAMP on 4EBP1-cap
binding. 4EBP1 was dissociated from eIF-4E upon the treat-
ment of cells with either forskolin or insulin (Fig. 7A). Pre-
treatment with rapamycin did not induce a cAMP-mediated
dissociation of 4EBP1 from eIF-4E. We found that the silenc-
ing of PDE4D decreased the interaction of 4EBP1 with eIF-
4E, whereas the overexpression of either wt PDE4D or the
PDE4D catalytic region (F2) increased the interaction of
4EBP1 with eIF-4E (Fig. 7B and D). This result correlated
with the regulation of mTORC1 activity by PDE4D5 (Fig. 2C
and 6D). We also found that PDE4D had a negative effect on
cap-dependent translation, as measured by the relative lucif-
erase assay (Fig. 7C and E). These results support the hypoth-
esis that PDE4D is a cAMP-dependent regulator not only of
mTORC1 activation but also of cap-dependent translation, a
pivotal cellular downstream process regulated by mTORC1.
DISCUSSION
Here, we made the novel discovery that cAMP signaling is
linked to the mTORC1 pathway via a direct interaction be-
tween PDE4D and Rheb. We propose three key aspects by
which cAMP mediates mTORC1 activation. First, the cAMP
signal activates mTORC1 through Rheb, rather than through
either TSC or PKA, thereby inducing the initiation of cap-
dependent translation. Second, we propose that the decisive
mechanism of mTORC1 activity controlled by cAMP is dy-
namic and involves the cAMP-dependent release of Rheb from
PDE4D to allow the association of Rheb with mTORC1.
Third, we suggest that PDE4D serves as a molecular sensor
that mediates the cAMP regulation of mTORC1. In conclu-
sion, our findings suggest that the dynamic PDE4D-Rheb in-
teraction is a key mediator of cAMP-mediated mTORC1 ac-
tivation.
These findings have led us to suggest a novel mechanism for
Rheb in cAMP-induced mTORC1 activation. Since Rheb is
the immediate upstream activator of mTOR and is regulated
by various signals via the GAP activity of TSC, it has been
considered to provide a molecular gate that transmits signals to
mTOR (10, 23, 38, 48, 51, 68, 76, 84, 96). Although most
investigations have focused on the negative control of Rheb by
the GAP activity of TSC, several investigators proposed that
Rheb regulation is independent of TSC (3, 35, 44, 45). Indeed,
a recent study suggested that translationally controlled tumor
protein (TCTP) functions as a guanine nucleotide exchange
factor (GEF) for Rheb, which results in the activation of
mTORC1 (35). Another study demonstrated that Bnip3, a
hypoxia-inducible Bcl-2 homology 3 domain-containing pro-
tein, mediates the hypoxia-induced inhibition of mTOR by
interacting with Rheb (45). Additionally, FKBP38 (immu-
nophilin FK506 binding protein, 38kDa) has been identified as
a direct binding partner of Rheb and an inhibitor of mTORC1
(3), and in our previous work (44), we showed that glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) could regulate
mTORC1 activity through direct interactions with Rheb in
response to glycolytic flux. The study that we describe here
suggests that the novel cAMP-mediated regulatory mechanism
of Rheb is independent of both the GAP activity of TSC and
the guanine nucleotide binding status of Rheb (Fig. 1E and 5A
to C). Thus, Rheb may be a central mediator that links diverse
signals to the mTORC1 pathway.
cAMP-specific PDEs are known to negatively regulate
cAMP signaling via the hydrolysis of cAMP (16, 31). Of the
various PDE families that hydrolyze cAMP, members of the
PDE4 family are ubiquitously expressed, play a key role in
maintaining the compartmentalization of cAMP signaling, and,
from the use of selective inhibitors and knockdown studies,
have been shown to play key roles in a variety of important
processes such as inflammation, learning, and memory (16, 17,
31–33). Although all PDE4 family members have similar struc-
tures in the catalytic domains and similar enzymatic activities,
each PDE4 isoform is characterized by a unique N-terminal
region that invariably facilitates targeting to specific protein
complexes (31–33). Complex formation with particular binding
partners enables PDE4s to target particular intracellular loca-
tions or particular cytosolic signaling complexes, which regu-
late localized intracellular cAMP levels, modulate the suscep-
tibility of sequestered cAMP effectors to elevations in cAMP
levels, and confer functional specificity (31, 33). Here, we show
that PDE4D, and in particular PDE4D5, can interact with
Rheb and thereby serve as a cAMP-specific negative regulator
of mTORC1, independent of its enzymatic activity. In agree-
ment with this novel paradigm for cAMP signaling, we have
shown that GAPDH regulates mTORC1 activity through di-
rect interaction with Rheb in response to glycolytic flux (44),
and indeed, PDE7A1 has been shown to inhibit PKA through
interactions with the PKA C domain independently of its
cAMP hydrolysis activity (27).
When the cellular cAMP level rises, its two central effectors
are PKA (81, 83) and exchange protein activated by cAMP
(EPAC) (9). PKA phosphorylates the long PDE4D isoforms,
thereby activating the short-term hydrolysis activity of PDE4D
and contributing a major part of the cellular desensitization
process to cAMP (54, 59, 70, 71, 89). However, PKA is clearly
not involved in the novel function of PDE4D5 that we report
here because the inhibition of PKA did not affect the ability of
elevated cAMP levels to disrupt the Rheb-PDE4D5 interac-
tion, and critically, in vitro, the interaction between purified
PDE4D and purified Rheb was disrupted solely by the addition
of cAMP. The latter experiment unequivocally shows that the
addition of cAMP to a mixture of PDE4D and Rheb severely
compromises the interaction. This led us to consider that the
catalytic domain of PDE4D, which binds cAMP, may itself
function as a molecular sensor for changes in the cAMP level
and transmit them to the mTOR signaling system. Indeed, we
were able to demonstrate here that cAMP induces the disso-
ciation of PDE4D5 from Rheb. Certainly, this would provide
sensor functioning at physiological levels of cAMP, as PDE4
isoforms exhibit Km values for cAMP in the 1 to 4.0 M range,
which correlates with the typical ranges (1 to 30 M) of intra-
cellular cAMP concentrations (32). Additionally, there is a
precedent for the PDE4 catalytic subunit undergoing confor-
mational changes upon binding to various selective inhibitors
(32, 34, 73, 85); it is possible that conformational changes occur
upon cAMP binding to PDE4 isoforms in complexes with spe-
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FIG. 7. PDE4D has a negative effect on cap-dependent translation efficiency. (A) cAMP decreases the interaction between 4EBP1 and the cap
structure. After 24 h of serum deprivation, HEK293 cells were preincubated with or without serum-free medium containing 10 nM rapamycin for
45 min and were then treated with 10 M forskolin or 20 nM insulin for 5 min. The cell lysates were incubated with 10 l of m7-GTP Sepharose
beads for 4 h. The resulting beads were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The results shown are
representative of two independent experiments. (B) PDE4D knockdown disrupts the interaction between 4EBP1 and the cap structure. HEK293
cells were transfected with either control or PDE4D siRNA. After 24 h, cells were deprived of serum for 24 h and then treated with 10 M forskolin
for 5 min. After the pulldown assay was performed, the resulting beads were subjected to SDS-PAGE and immunoblotted with the respective
antibodies. The results shown are representative of two independent experiments. (C) PDE4D knockdown enhances cap-dependent translation.
HEK293 cells were transfected with either control or PDE4D siRNA. After 24 h, cells were deprived of serum for 24 h and then treated with 10
M forskolin for 36 h. The resulting lysates were measured by the dual-luciferase reporter assay. The results shown are representative of two
independent experiments. NT, no treatment. (D) PDE4D5 overexpression enhances the interaction between 4EBP1 and the cap structure.
HEK293 cells were transfected with the indicated constructs. After 36 h, the cell lysates were incubated with 10 l of m7-GTP Sepharose beads
for 4 h. The resulting beads were subjected to SDS-PAGE and immunoblotted with the respective antibodies. The results shown are representative
of two independent experiments. (E) PDE4D5 overexpression inhibits cap-dependent translation. HEK293 cells were transfected with the
indicated constructs. After 36 h, the resulting lysates were measured by the dual-luciferase reporter assay. The results shown are representative
of two independent experiments.
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cific partner proteins. All of the PDE4 crystal structures re-
ported to date have focused on the core catalytic unit with
various bound inhibitors (88). However, there are no crystal
structures of either full-length PDE4 or the enzyme in complex
with proteins that sequester it, and thus, we have no knowledge
of structural changes from such approaches. However, binding
studies of inhibitors, phosphorylation states, and the binding of
partner proteins have all identified various marked changes in
activity, thermostability, and inhibitor binding that are consis-
tent with profound conformational changes (32, 33, 73). In-
deed, there is a large amount of literature indicating that
PDE4 isoforms can adopt multiple conformational states (32,
34, 73). We suggest here that the release of Rheb from PDE4D
might thus be dynamically controlled in cells by cAMP binding.
Moreover, we also observed that isoproterenol, a -adrenergic
receptor agonist that increases cAMP levels, induced the dis-
sociation of PDE4D5 from Rheb in cells. These results imply
that the regulatory mechanism of Rheb by PDE4D5 may con-
sist of the binding of cAMP to the PDE4D catalytic site, which
then displaces Rheb from PDE4D5. Whether this occurs
though competition between Rheb and cAMP for binding to
PDE4D5 or through an allosteric conformational change re-
mains to be determined. It is interesting that the RACK1
signaling scaffold binds to PDE4D5 not only at a site within its
unique N-terminal domain but also at the catalytic domain,
where it abuts the cAMP binding site (7) and causes a confor-
mational change that is detectable through an altered binding
of the inhibitor rolipram to this enzyme (94). A crystal struc-
ture of the complex of PDE4D and Rheb may provide critical
evidence for this hypothesis, although this will be a challenging
endeavor, since to date, the full-length PDE4 structure has not
been obtained due to the propensity of the full-length enzyme
to aggregate.
It was shown previously that the major function of cAMP is
to modulate the transcription of target genes through the
PKA-CREB pathway (64, 72). However, there have been a few
reports showing the cAMP-mediated regulation of translation;
for example, it was shown previously that cAMP induces the
mRNA translation of tyrosine hydroxylase in dopaminergic
neurons (14, 22, 92). Here, we show that cAMP also has a
positive effect on cap-dependent translation via the mTORC1
pathway. As a general rule, the regulation of translation pro-
vides cells with the flexibility to rapidly respond to environ-
mental alterations under certain conditions, such as apoptosis,
that require immediate changes in protein levels (29). If cAMP
regulates both transcription and translation, cells may have
diverse and rapid responses for various environmental condi-
tions. Further studies are needed to identify the environmental
conditions that induce cAMP-mediated cap-dependent trans-
lation.
mTORC1 is a molecular hub that receives various signals
from the extracellular environment to modulate protein syn-
thesis. Cells may have developed multiple ways to regulate
mTORC1 signaling in response to diverse environmental cues.
The best-characterized upstream regulators of mTORC1 are
TSC and Rheb. In addition to regulation by TSC-Rheb,
PRAS40 and Rag GTPase have been identified as mTORC1
regulators in response to insulin and amino acids, respectively
(65, 66, 86). Here, we have identified a novel function for
PDE4D in cAMP-mediated mTORC1 activation. According to
our model, PDE4D has dual roles as a specific sensor of cAMP
and a cAMP-hydrolyzing enzyme. When the cellular cAMP
level rises, PDE4D recognizes the increased level and dissoci-
ates from Rheb, thereby enhancing the interaction between
Rheb and mTOR. Simultaneously, free PDE4D may function
as a negative-feedback regulator via the hydrolysis of cAMP
that surrounds mTORC1. Thus, cells may have an advanced
mechanism that allows mTORC1 to immediately respond to
the cAMP signal via the dual function of PDE4D. The possible
negative regulation of PDE4D by Rheb binding under basal
conditions and of the cAMP-induced activation of PDE4D
may be interesting for future studies aimed at elucidating ad-
ditional details of the cross talk between the cAMP and mTOR
pathways.
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